In 93 patients with biopsy proven primary hepatocellular carcinoma (PHC) from Uganda, Zambia, and the U.S.A. serologic evidence of hepatitis B virus (BHV) infection was sought for. Patients were tested for hepatitis B surface antigen (HBsAg) and its antibody (anti HBs), antibody to the hepatitis B core antigen (anti HBc), hepatitis B e antigen (HBeAg), and its antibody (anti HBe). Active HBV infection, as indicated by positive tests for HBsAg (with or without anti HBs) and anti HBc (without anti HBs), was present in 62% of PHC patients (58 of 93), in contrast with 10% of African controls (9 of 90), and less than 1% of most U.S.A. adult populations reported in the literature. The presence of HBeAg or anti HBe was rare among PHC patients and controls.
ASJC Scopus subject areas
- Cancer Research